Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 40%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 20%Moderate 2 · 40%High 0 · 0%

Chemotherapy with TKI vs chemotherapy alone

Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC

Chemotherapy with TKI may leads to higher any adverse events (grade ≥3) compared with chemotherapy alone (low certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
RR 1.23 [1.02, 1.49]
4 studies · 548 participants
Low

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Adverse events (grade ≥ 3) · newly‐diagnosed EOC

Chemotherapy with TKI followed by TKI maintenance probably leads to higher any adverse event grade ≥ 3 compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
RR 1.31 [1.11, 1.55]
1 study · 188 participants
Moderate

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC

The review found no eligible studies for this question.

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Chemotherapy with TKI (peptide‐Fc fusion protein) vs chemotherapy alone

Adverse events (grade ≥ 3) · recurrent EOC

The review found no eligible studies for this question.

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone

Adverse events (grade ≥ 3) · newly‐diagnosed EOC

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI… probably leads to lower any adverse event grade ≥ 3 compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1011 participants
Moderate